During this meeting, the advisory committee will: Review available safety and efficacy data for BPC-157, including preclinical studies and any available clinical evidence Consider public comments submitted by patients, practitioners, and industry stakeholders Evaluate the clinical need for compounded BPC-157 and the patient populations that would benefit Assess the compounding quality considerations specific to peptide formulations Issue a recommendation to the FDA on whether BPC-157 should be included on the 503A compounding list Possible outcomes include: Positive recommendation: PCAC advises the FDA to add BPC-157 to the 503A list, clearing the way for legal compounding nationwide
Plus, people tend to be open to trying it
Talking to Your GP or Specialist About Weight Management Options Speak to your GP about licensed options such as semaglutide 2.4 mg (Wegovy) under NICE TA875 or tirzepatide (Mounjaro)
Your body naturally produces these enzymes in the saliva, stomach, pancreas, and small intestine
Iqbal Z, Sun J, Yang H et al (2022) Recent Developments to Cope the Antibacterial Resistance via -Lactamase Inhibition